The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1710
ISSUE 1710
September 2, 2024
Issue 1710
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Drugs for COPD
September 2, 2024 (Issue: 1710)
The main goals of treatment of chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
prevent disease progression, and reduce mortality.
GOLD (Global Initiative for Chronic...more
- Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: 2024 report. Available at www.goldcopd.org. Accessed August 14, 2024.
- Drugs for smoking cessation. Med Lett Drugs Ther 2019; 61:105.
- N Lindson et al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analysis. Cochrane Database Syst Rev 2023; 9:CD015226. doi:10.1002/14651858.cd015226.pub2
- JJ Rose et al. Cardiopulmonary impact of electronic cigarettes and vaping products: a scientific statement from the American Heart Association. Circulation 2023; 148:703. doi:10.1161/cir.0000000000001160
- Influenza vaccine for 2023-2024. Med Lett Drugs Ther 2023; 65:161.
- S Mulpuru et al. Effectiveness of influenza vaccination on hospitalizations and risk factors for severe outcomes in hospitalized patients with COPD. Chest 2019; 155:69. doi:10.1016/j.chest.2018.10.044
- F Froes et al. Pneumococcal vaccination and chronic respiratory diseases. Int J Chron Obstruct Pulmon Dis 2017; 12:3457. doi:10.2147/copd.s140378
- CDC. Pneumococcal vaccine recommendations. June 27, 2024. Available at: https://bit.ly/4cfGeZl. Accessed August 14, 2024.
- B McCarthy et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015; 2:CD003793. doi:10.1002/14651858.cd003793.pub3
- H-Y Lu et al. Effects of early pulmonary rehabilitation on hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 2023; 18:881. doi:10.2147/copd.s397361
- PK Lindenauer et al. Association between initiation of pulmonary rehabilitation after hospitalization for COPD and 1-year survival among medicare beneficiaries. JAMA 2020; 323:1813. doi:10.1001/jama.2020.4437
- DP Tashkin et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359:1543. doi:10.1056/nejmoa0805800
- M Decramer et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374:1171. doi:10.1016/s0140-6736(09)61298-8
- Aclidinium bromide (Tudorza Pressair) for COPD. Med Lett Drugs Ther 2012; 54:99.
- Seebri Neohaler and Utibron Neohaler for COPD. Med Lett Drugs Ther 2016; 58:39.
- Umeclidinium (Incruse Ellipta) for COPD. Med Lett Drugs Ther 2015; 57:63.
- Revefenacin (Yupelri) for COPD. Med Lett Drugs Ther 2019; 61:14.
- S Singh et al. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300:1439. doi:10.1001/jama.300.12.1439
- KMC Verhamme et al. Use of tiotropium Respimat soft mist inhaler versus Handihaler and mortality in patients with COPD. Eur Respir J 2013; 42:606. doi:10.1183/09031936.00005813
- S Singh et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011; 342:d3215. doi:10.1136/bmj.d3215
- M-T Wang et al. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study. JAMA Intern Med 2018; 178:229. doi:10.1001/jamainternmed.2017.7720
- B Celli et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010; 137:20. doi:10.1378/chest.09-0011
- RA Wise et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013; 369:1491. doi:10.1056/nejmoa1303342
- RA Wise et al. Effect of aclidinium bromide on major cardiovascular events and exacerbations in high-risk patients with chronic obstructive pulmonary disease: the ASCENT-COPD randomized clinical trial. JAMA 2019; 321:1693. doi:10.1001/jama.2019.4973
- KM Kew et al. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013; 10:CD010177. doi:10.1002/14651858.cd010177.pub2
- M Lipari et al. Dual- versus mono-bronchodilator therapy in moderate to severe COPD: a meta-analysis. Ann Pharmacother 2020; 54:1232. doi:10.1177/1060028020932134
- HA Farne and CJ Cates. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015; 10:CD008989. doi:10.1002/14651858.cd008989.pub3
- H Ni et al. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev 2018; 12:CD011594. doi:10.1002/14651858.cd011594.pub2
- CF Vogelmeier et al. Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial. Ther Adv Respir Dis 2020; 14:1. doi:10.1177/1753466620968500
- DA Lipson et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 2018; 378:1671. doi:10.1056/nejmoa1713901
- A Papi et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 2018; 391:1076. doi:10.1016/s0140-6736(18)30206-x
- DA Lipson et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2020; 201:1508. doi:10.1164/rccm.201911-2207oc
- KF Rabe et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med 2020; 383:35. doi:10.1056/nejmoa1916046
- D Singh et al. Blood eosinophils and chronic obstructive pulmonary disease: a Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 review. Am J Respir Crit Care Med 2022; 206:17. doi:10.1164/ccm.202201- 0209pp
- H Magnussen et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014; 371:1285. doi:10.1056/nejmoa1407154
- H Watz et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016; 4:390. doi:10.1016/s2213-2600(16)00100-4
- KR Chapman et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med 2018; 198:329. doi:10.1164/rccm.201803-0405oc
- H Magnussen et al. Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study. Respir Res 2021; 22:25. doi:10.1186/s12931-021-01615-0
- KM Kew and A Seniukovich. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; 3:CD010115. doi:10.1002/14651858.cd010115.pub2
- Ensifentrine (Ohtuvayre) for COPD. Med Lett Drugs Ther 2024; 66:131.
- A Anzueto et al. Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE trials). Am J Respir Crit Care Med 2023; 208:406. doi:10.1164/rccm.202306-0944oc
- Center for Drug Evaluation and Research. Risk assessment and risk mitigation review(s). Ensifentrine. June 12, 2024. Available at: https://bit.ly/4fsZ2ra. Accessed August 14, 2024.
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- Roflumilast (Daliresp) for COPD. Med Lett Drugs Ther 2011; 53:59.
- PMA Calverley et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374:685. doi:10.1016/s0140-6736(09)61255-1
- J Chong et al. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2017; 11:CD002309. doi:10.1002/14651858.cd002309.pub5
- RK Albert et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365:689. doi:10.1056/nejmoa1104623
- S Uzun et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebocontrolled trial. Lancet Respir Med 2014; 2:361. doi:10.1016/s2213-2600(14)70019-0
- RL Woosley et al. QTdrugs list. Available at: www.crediblemeds. org. Accessed August 14, 2024.
- PJ Barnes. Theophylline. Am J Respir Crit Care Med 2013; 188:901. doi:10.1164/rccm.201302-0388pp
- G Devereux et al. Effect of theophylline as adjunct to inhaled corticosteroids on exacerbations in patients with COPD: a randomized clinical trial. JAMA 2018; 320:1548. doi:10.1001/jama.2018.14432
- Long-Term Oxygen Treatment Trial Research Group. A randomized trial of long-term oxygen for COPD with moderate desaturation. N Engl J Med 2016; 375:1617. doi:10.1056/nejmoa1604344
- JK Stoller et al. Oxygen therapy for patients with COPD: current evidence and the long-term oxygen treatment trial. CHEST 2010; 138:179. doi:10.1378/chest.09-2555
- CA Verberkt et al. Effect of sustained-release morphine for refractory breathlessness in chronic obstructive pulmonary disease on health status: a randomized clinical trial. JAMA Intern Med 2020; 180:1306. doi:10.1001/jamainternmed.2020.3134
- M Ekström et al. Effect of regular, low-dose, extended-release morphine on chronic breathlessness in chronic obstructive pulmonary disease: the BEAMS randomized clinical trial. JAMA 2022; 328:2022. doi:10.1001/jama.2022.20206
- SP Bhatt et al. Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation. N Engl J Med 2024; 390:2274. doi:10.1056/nejmoa2401304
- GJ Criner et al. Benralizumab for the prevention of COPD exacerbations. N Engl J Med 2019; 381:1023. doi:10.1056/nejmoa1905248
- NIH. Efficacy and safety of benralizumab in moderate to very severe chronic obstructive pulmonary disease (COPD) with a history of frequent exacerbations (RESOLUTE). Available at: https://bit.ly/3X0xKBb. Accessed August 14, 2024.
- D Singh et al. Tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease (COPD): efficacy and safety from the phase 2a COURSE study (abstract). Am J Respir Crit Care Med 2024; 209:A2782. doi:10.1164/ajrccm-conference.2024.209.1_MeetingAbstracts.A2782
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1710
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.